Educating physicians and other healthcare professionals with the most cutting-edge information available related to hemostasis management.
The traditional model of coagulation, which comprises intrinsic and extrinsic pathways, does not reflect how blood clots in vivo. For example, the model cannot explain why hemophiliacs bleed when they have an intact FVIIa/tissue factor (“extrinsic”) pathway or why prolonged aPTTs and PTs are not always associated with bleeding. Emerging knowledge of the critical role of cells in regulating hemostasis has led to the development of a model of coagulation that better explains bleeding and thrombosis in vivo. This presentation will review the important role of different cell surfaces in coagulation, coagulopathic microvascular bleeding, and thrombosis. In addition, the slide presentation will discuss the processes involved in fibrinolysis.
Navigating the Coagulation Cascade is intended to provide an overview of the cell-based model of coagulation for transfusion specialists, hematologists, and other healthcare professionals.
After completing this continuing medical education (CME) activity, participants should be able to:
This activity has expired.
This activity has expired.
This activity has expired.
It is the policy of the FCG Institute for Continuing Education that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussion of unlabeled or unapproved uses of drugs or medical devices. Faculty disclosure statements can be found with their biographical sketches.
When individuals in a position to control or influence the development of the content have reported Financial Relationships with one or more commercial interests, The FCG Institute for Continuing Education utilizes a process to identify and resolve potential conflicts to ensure that the content presented is free of commercial bias. The content of this presentation was vetted through The Institute’s process of peer review and content validation and modified as required to meet this standard.
This educational activity may include discussion of drugs or devices or uses of drugs and devices, that have not been approved by the FDA or have been approved by the FDA for specific uses only. It is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. The FCG Institute for Continuing Education is committed to the free exchange of medical education. Inclusion of any product or device discussion, including discussion of investigational or off-label uses, does not imply endorsement by The Institute of the uses, products, or techniques presented.
This CME/CE activity is designed for use by healthcare professionals for educational purposes only. The information and opinions expressed by the faculty are their own and do not necessarily reflect those of The FCG Institute. The FCG Institute for Continuing Education does not define a standard of care, nor does it intend to dictate an exclusive course of management but presents through the educational activities it sponsors recognized methods and techniques of clinical practice for consideration by physicians and other healthcare providers for incorporation into their practices. Participants should use their own clinical judgment before applying information, whether provided here or by others, for any professional use.
Maureane Hoffman, MD, PhD
Director of Transfusion Services
Director, Hematology and Flow Cytometry Laboratories
Durham VA Medical Center
Professor of Pathology and Immunology
Duke University
Durham, North Carolina
Adjunct Professor of Medicine
University of North Carolina
Chapel Hill, North Carolina


The FCG Institute
for Continuing Education gratefully acknowledges an educational
grant from Novo Nordisk Inc. in support of this CME
activity.
© Copyright by The Institute. All rights reserved. | Privacy Policy